FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 308:1489-1493 June 23, 1983 Number 25 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We have previously demonstrated that six weeks of prophylaxis with interferon-alpha delays cytomegalovirus excretion and decreases viremia in recipients of kidney transplants. In a double-blind trial to evaluate the effects of a longer course of prophylaxis, we gave either 3 X 10(6) units of interferon or placebo intramuscularly to 42 patients before transplant surgery was performed. After surgery, doses were given three times a week for six weeks and then twice a week for eight weeks (total of 102 X 10(6) units). Clinical signs of cytomegalovirus infection were markedly reduced in interferon recipients. These signs developed in 7 of 22 placebo recipients and 1 of 20 interferon recipients (P = 0.03). Opportunistic superinfections (Aspergillus fumigatus and Pneumocystis carinii) occurred only in patients given placebo. Cytomegalovirus-associated glomerulopathy developed in one interferon recipient and three placebo recipients. Survival of patients and grafts was equivalent in both treatment groups, and minimal toxicity was observed with interferon. In seropositive renal-transplant recipients, interferon-alpha affords effective prophylaxis against serious cytomegalovirus infections.

This article has been cited by other articles:

• Kvale, E. O., Dalgaard, J., Lund-Johansen, F., Rollag, H., Farkas, L., Midtvedt, K., Jahnsen, F. L., Brinchmann, J. E., Olweus, J. (2006). CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood 107: 2022-2029 [Abstract] [Full Text]  
• Griffiths, P. D. (2002). The treatment of cytomegalovirus infection. J Antimicrob Chemother 49: 243-253 [Abstract] [Full Text]  
• (2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother 45: 729-748 [Full Text]  
• Dousset, B., Conti, F., Houssin, D., Calmus, Y. (1994). Acute Vanishing Bile Duct Syndrome after Interferon Therapy for Recurrent HCV Infection in Liver-Transplant Recipients. NEJM 330: 1160-1161 [Full Text]  
• Bennett, M. A., Allen, R. D. (1990). High-Technology Home Pharmacotherapy, II: An Overview of the Newest Home Therapies. Journal of Pharmacy Practice 3: 40-47 [Abstract]